(April 18, 2024, 2:29 PM EDT) -- ALEXANDRIA, Va. — Despite recognition that three steps outlined in a Natera Inc. patent for analyzing mutations in cell-free DNA were not new on their own or in combination, a patent examiner wrongly allowed the claims based on two amendments that would also be obvious to a person skilled in the art (POSA), a petitioner for inter partes review (IPR) maintains in an April 17 filing with the Patent Trial and Appeal Board....